Fulcrum Therapeutics (FULC) Non Operating Income (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Non Operating Income data on file, last reported at $3.3 million in Q1 2026.

• On a quarterly basis, Non Operating Income rose 19.91% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $10.4 million, a 12.71% decrease from a year earlier, with the FY2025 full-year figure at $9.9 million, down 18.76% from the prior year.
• Non Operating Income for Q1 2026 stood at $3.3 million, up from $2.4 million in the prior quarter.
• Over the last five years, Non Operating Income for FULC reached as high as $3.5 million in Q2 2023 and fell as low as $70000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $2.4 million across 5 years, with a median of $2.9 million in 2024.
• Across the five-year window, Non Operating Income jumped 4415.71% in 2023 and sank 34.02% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $1.8 million in 2022, then jumped by 76.06% to $3.2 million in 2023, then slipped by 11.59% to $2.9 million in 2024, then dropped by 17.55% to $2.4 million in 2025, then surged by 39.68% to $3.3 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $3.3 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.